293 related articles for article (PubMed ID: 23642267)
1. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Müller T
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
[TBL] [Abstract][Full Text] [Related]
2. The safety of istradefylline for the treatment of Parkinson's disease.
Müller T
Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
[TBL] [Abstract][Full Text] [Related]
3. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
[TBL] [Abstract][Full Text] [Related]
4. The role of istradefylline in the Parkinson's disease armamentarium.
Müller T
Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
[TBL] [Abstract][Full Text] [Related]
5. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
[TBL] [Abstract][Full Text] [Related]
6. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
Kanda T; Uchida S
Int Rev Neurobiol; 2014; 119():127-50. PubMed ID: 25175964
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease.
Knebel W; Rao N; Uchimura T; Mori A; Fisher J; Gastonguay MR; Chaikin P
J Clin Pharmacol; 2012 Oct; 52(10):1468-81. PubMed ID: 22162533
[TBL] [Abstract][Full Text] [Related]
9. Istradefylline for the treatment of Parkinson's disease.
Park A; Stacy M
Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
[TBL] [Abstract][Full Text] [Related]
10. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
11. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
[TBL] [Abstract][Full Text] [Related]
12. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
[TBL] [Abstract][Full Text] [Related]
13. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Pinna A; Wardas J; Simola N; Morelli M
Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
Ko WKD; Camus SM; Li Q; Yang J; McGuire S; Pioli EY; Bezard E
Neuropharmacology; 2016 Nov; 110(Pt A):48-58. PubMed ID: 27424102
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Tao Y; Liang G
Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
[TBL] [Abstract][Full Text] [Related]
16. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
Perez-Lloret S; Merello M
Expert Opin Pharmacother; 2014 Jun; 15(8):1097-107. PubMed ID: 24673462
[TBL] [Abstract][Full Text] [Related]
17. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
[TBL] [Abstract][Full Text] [Related]
19. Istradefylline - a first generation adenosine A
Jenner P; Mori A; Aradi SD; Hauser RA
Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
[No Abstract] [Full Text] [Related]
20. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Chen W; Wang H; Wei H; Gu S; Wei H
J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
